文献速递妇科

非唑奈坦治疗绝经相关血管舒缩症状的疗效与安全性:一项Meta分析

Efficacy and Safety of Fezolinetant for the Treatment of Menopause-Associated Vasomotor Symptoms: A Meta-analysis.
PubMed 文献 · Obstet Gynecol · 2024-01-16

该Meta分析纳入5项随机对照试验(6篇报告)共2168名绝经女性,评估非唑奈坦与安慰剂相比治疗中重度血管舒缩症状的疗效与不良事件。非唑奈坦显著降低血管舒缩症状频率,合并均数差为2.62(95%CI 1.84-3.41),并改善睡眠质量。

要点

  • 非唑奈坦显著降低中重度血管舒缩症状频率,合并均数差2.62(95%CI 1.84-3.41)。
  • 与安慰剂相比,非唑奈坦组MENQOL评分合并均数差为-0.60(95%CI -0.92至-0.28)。
  • 非唑奈坦与安慰剂相比改善睡眠质量。

核心结论

  • 非唑奈坦可有效降低绝经后女性中重度血管舒缩症状频率并改善睡眠障碍。

研究设计与样本

  • 系统检索PubMed/MEDLINE、ClinicalTrials.gov、EMBASE、Cochrane Database、Scopus和WHO国际临床试验注册平台至2023年6月,纳入5项随机对照试验(6篇报告)共2168名参与者。
  • 使用Cochrane RoB 2工具评估偏倚风险,采用GRADE方法对证据质量进行分级,效应量数据采用随机效应模型合并。

主要发现

  • 非唑奈坦显著降低血管舒缩症状频率,合并均数差为2.62(95%CI 1.84-3.41)。
  • 与安慰剂相比,非唑奈坦组MENQOL评分的合并均数差为-0.60(95%CI -0.92至-0.28)。
  • 血管舒缩症状频率的平均改善百分比为22.51%(95%CI 15.35-29.67)。
  • 与安慰剂相比,非唑奈坦与睡眠质量改善相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the efficacy and adverse events of fezolinetant for treating vasomotor symptoms (VMS) of menopause. DATA SOURCES: PubMed/MEDLINE, ClinicalTrials.gov , EMBASE, Cochrane Database, Scopus, and WHO International Clinical Trials Registry Platform were searched through June 2023 for publications and randomized controlled trials on fezolinetant compared with placebo in menopausal women who experienced moderate-to-severe VMS. METHODS OF STUDY SELECTION: Our literature search identified 330 articles, of which five studies with six reports were included in our meta-analysis per our eligibility criteria. TABULATION, INTEGRATION, AND RESULTS: The risk of bias was evaluated using Cochrane's RoB 2 (Risk of Bias version 2) tool, quality of evidence was graded using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach, and outcome measures data for effect size were pooled in random-effects model and rated. A total of 2,168 participants from five randomized clinical trials (six reports) were included. Fezolinetant significantly lowered VMS frequency, with pooled mean difference of 2.62 (95% CI, 1.84-3.41). The pooled mean difference for fezolinetant compared with placebo for the MENQOL (Menopause-Specific Quality of Life) measure was -0.60 (95% CI, -0.92 to -0.28), and the mean percentage improvement in VMS frequency was 22.51% (95% CI, 15.35-29.67). Fezolinetant was associated with improvement in sleep quality when compared with placebo. CONCLUSION: Fezolinetant is effective in lowering moderate-to-severe VMS frequency and sleep disturbances in postmenopausal women. SYSTEMATIC REVIEW REGISTRATION: PROSPERO, CRD42023427616.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Bonga KN, Mishra A, Maiti R, et al. Efficacy and Safety of Fezolinetant for the Treatment of Menopause-Associated Vasomotor Symptoms: A Meta-analysis. Obstet Gynecol. 2024. PMID: 38227939. doi:10.1097/AOG.0000000000005508

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。